Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc.. Nivolumab (Opdivo) for first-line treatment of advanced melanoma. Lansdale: HAYES, Inc.. Healthcare Technology Brief Publication. 2015 Indexing Status Subject indexing assigned by CRD MeSH Antibodies, Monoclonal; Humans; Melanoma Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence HAYES, Inc., 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218 Email: hayesinfo@hayesinc.com AccessionNumber 32016000092 Date abstract record published 27/01/2016 |